インデックス付き
- Jゲートを開く
- Genamics JournalSeek
- アカデミックキー
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- パブロン
- ジュネーブ医学教育研究財団
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Entecavir in Severe Acute Hepatitis B
Pervaiz Majeed Zunga
An estimated 350 million persons worldwide are chronically infected with HBV [1]. The average estimated carrier rate of Hepatitis B Virus (HBV) in India is 4%, with a total pool of approximately 36 million carriers. Most of India’s carrier pool is established in early childhood, predominantly by horizontal spread due to crowded living conditions and poor hygiene. Acute and subacute liver failure is common complications of viral hepatitis in India and HBV is reckoned to be the etiological agent in 42% and 45% of adult cases, respectively. In conclusion, hepatitis B is a major public health problem in India and will continue to be until appropriate nationwide vaccination programmes and other control measures are established.